Cargando…
Immunotherapy for Prostate Cancer Enters Its Golden Age
In the United States, prostate cancer is the most frequent malignancy in men and ranks second in terms of mortality. Although recurrent or metastatic disease can be managed initially with androgen ablation, most patients eventually develop castration-resistant disease within a number of years, for w...
Autores principales: | Boikos, Sosipatros A., Antonarakis, Emmanuel S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3403579/ https://www.ncbi.nlm.nih.gov/pubmed/22844202 http://dx.doi.org/10.4137/CMO.S7475 |
Ejemplares similares
-
Aging and immunotherapies: New horizons for the golden ages
por: Hamilton, Jamie A.G., et al.
Publicado: (2020) -
Chemotherapy and its evolving role in the management of advanced prostate cancer
por: Schweizer, Michael T, et al.
Publicado: (2014) -
Golden Age of Immunotherapy: Challenges and Opportunities
por: Chung, Yeonseok, et al.
Publicado: (2022) -
Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
por: Golshayan, Ali R, et al.
Publicado: (2013) -
Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)